Sign Up to like & get
recommendations!
0
Published in 2017 at "Diagnostic microbiology and infectious disease"
DOI: 10.1016/j.diagmicrobio.2017.02.018
Abstract: The β-lactamase inhibitor relebactam inactivates class A β-lactamases, including KPC-type carbapenemases, and class C β-lactamases. Relebactam combined with imipenem is in clinical development for several indications, including hospital-acquired and ventilator-associated pneumonia. Employing CLSI-defined broth microdilution…
read more here.
Keywords:
lower respiratory;
relebactam;
imipenem relebactam;
respiratory tract ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Diagnostic microbiology and infectious disease"
DOI: 10.1016/j.diagmicrobio.2021.115421
Abstract: Bloodstream infections (BSI) are often caused by drug-resistant pathogens, and novel antimicrobials are needed. We examined the activity of imipenem/relebactam against BSI pathogens from US and Canada: >99% of non-Morganellaceae Enterobacterales, including 100% of MDR…
read more here.
Keywords:
bloodstream infections;
relebactam;
imipenem relebactam;
activity imipenem ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2020.1790525
Abstract: ABSTRACT Introduction The addition of the β-lactamase inhibitor relebactam to imipenem restores the antibacterial activity against the majority of multidrug resistant Gram-negative bacteria. Complicated urinary tract infections (UTIs) are predominantly caused by Gram-negative uropathogens. The…
read more here.
Keywords:
imipenem;
relebactam;
urinary tract;
complicated urinary ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Critical Care Medicine"
DOI: 10.1097/01.ccm.0000551637.82957.35
Abstract: Learning Objectives: Pseudomonas aeruginosa (PSA) is a common cause of infections in the intensive care unit (ICU) and notable for extensive antimicrobial resistance. Increasing carbapenem resistance among PSA, limits therapeutic options available to patients. Relebactam…
read more here.
Keywords:
relebactam;
psa;
vitro activity;
non susceptible ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Journal of medical microbiology"
DOI: 10.1099/jmm.0.001142
Abstract: Introduction. Infections attributable to carbapenem-resistant Gram-negative bacilli are increasing globally. New antimicrobial agents are urgently needed to treat patients with these infections.Aim. To describe susceptibility to the novel carbapenem-β-lactamase inhibitor combination imipenem-relebactam and comparators of…
read more here.
Keywords:
imipenem;
relebactam;
urinary tract;
imipenem relebactam ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00533-18
Abstract: Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a…
read more here.
Keywords:
imipenem;
relebactam;
negative bacilli;
gram negative ... See more keywords